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ABSTRACT
Investigation of the temporal trajectories of currently used neuropsychological tests is
critical to identifying earliest changing measures on the path to dementia due to
Alzheimer’s disease (AD). We used the Progression Score (PS) method to characterize
the temporal trajectories of measures of verbal memory, executive function, attention,
processing speed, language, and mental state using data spanning normal cognition, mild
cognitive impairment (MCI), and AD from 1661 participants with a total of 7839 visits
(age at last visit 77.6 SD 9.2) in the Baltimore Longitudinal Study of Aging and 1542
participants with a total of 4467 visits (age at last visit 59.9 SD 7.3) in the Wisconsin
Registry for Alzheimer’s Prevention. This method aligns individuals in time based on the
similarity of their longitudinal measurements to reveal temporal trajectories. As a
validation of our methodology, we explored the associations between the individualized
cognitive progression scores (Cog-PS) computed by our method and clinical diagnosis.
Digit span tests were the first to show declines in both data sets, and were detected
mainly among cognitively normal individuals. These were followed by tests of verbal
memory, which were in turn followed by Trail Making Tests, Boston Naming Test, and
Mini-Mental State Examination. Differences in Cog-PS across the clinical diagnosis
groups were statistically significant, highlighting the potential use of Cog-PS as
individualized indicators of disease progression. Identifying cognitive measures that are
changing in preclinical AD can lead to the development of novel cognitive tests that are
finely tuned to detecting earliest changes.
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ABBREVIATIONS
AD

Alzheimer’s disease

AVLT

Rey Auditory Verbal Learning Test

BLSA

Baltimore Longitudinal Study of Aging

CI

Cognitive impairment

Cog-PS

Cognitive progression score

CVLT

California Verbal Learning Test

MCI

Mild cognitive impairment

MMSE

Mini-Mental State Examination

WRAP

Wisconsin Registry for Alzheimer’s Prevention
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1.INTRODUCTION
Cognitive changes in Alzheimer’s disease (AD), in particular declines in episodic
memory, are detectable on neuropsychological testing up to fifteen years prior to clinical
diagnosis [1–4]. However, cognition has only limited cross-sectional association with
cerebral amyloid burden [5–11], which marks the beginning of preclinical AD according
to the National Institute on Aging–Alzheimer’s Association (NIA–AA) criteria [12].
Longitudinal studies have consistently shown that amyloid levels are associated with
greater rates of decline on tests of episodic memory [13–21], suggesting that amyloid
changes precede episodic memory declines. These findings indicate that despite the
fifteen-year period prior to diagnosis for detecting cognitive change, currently used
neuropsychological tests fall short of detecting changes in the earliest disease stages
where therapeutic intervention is hypothesized to be most promising. Therefore, there is a
need to develop cognitive tests and batteries that are more sensitive to changes in early
preclinical AD and that correlate better with AD-related neuroimaging measures.
Cognitive measures that are dynamic in preclinical disease can facilitate clinical trials
aimed at this early stage, as they can serve as outcome measures that are non-invasive
and cheaper to administer than neuroimaging evaluations.

In order to develop such cognitive tests or batteries, it is necessary to study the
neuroimaging correlates and temporal trajectories of currently used tests to identify
earliest changing measures. Various studies have investigated correlations between
cognitive measures and early AD-related neuroimaging markers [22–30]. In this work,
we focus on characterizing the trajectories of a collection of cognitive markers widely
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used in studies of aging and AD. The ideal study of preclinical AD markers would follow
cognitively normal individuals until they are diagnosed with dementia due to AD, and
retrospectively analyze the time courses of the markers of those who developed AD.
However, currently available sample sizes do not allow for cross-validation nor yield
adequate statistical power to conduct such a study. To overcome this limitation, several
statistical analysis approaches have been developed [31–36]. An important concept in a
subset of these approaches is the time-alignment of individuals. Here, we used the
Progression Score Model [36,37], a multivariate nonlinear mixed effects model, to
construct cognitive marker trajectories spanning normal cognition, mild cognitive
impairment (MCI), and AD stages by aligning individuals in time based on the similarity
of their marker profiles. The method incorporates longitudinal information in performing
this alignment and accounts for inter-individual differences in rate and baseline levels of
progression. The main premise of the method is that rather than using age as a proxy for
disease progression, we can obtain better disease progression indicators as well as
temporal trajectories for the biomarkers by aligning individuals in time based on the
similarity of their biomarker profiles. Time alignment of individuals allows us to study
the long-term trajectories of cognitive measures despite the availability of only a small
number of individuals who have traversed large extents of the cognitive trajectories. We
conducted separate analyses on two well-characterized longitudinal studies, the Baltimore
Longitudinal Study of Aging and the Wisconsin Registry for Alzheimer’s Prevention, in
order to delineate the trajectories of measures of verbal memory, executive function,
attention, processing speed, language, and mental state among individuals who are
cognitively normal, have MCI, or have dementia due to AD.
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The main aims of the analyses were to: 1) develop a standardized template of cognitive
changes against which individuals can be quantified, 2) present evidence of the validity
of the individualized scores obtained using the standardized cognitive template by
exploring their associations with clinical diagnosis, 3) identify the order in which
detectable changes begin to appear across cognitive tests, and 4) validate this identified
ordering using an independent approach at the individual level.

2.METHODS
Statistical methods used in the following analyses were applied separately to two ongoing
longitudinal cohort studies of human aging: the Baltimore Longitudinal Study of Aging
(BLSA) [38], initiated in 1958 and conducted by the Intramural Research Program of the
National Institute on Aging, and the Wisconsin Registry for Alzheimer’s Prevention
(WRAP) [39], initiated in 2001 and conducted by the University of Wisconsin
Alzheimer’s Institute.

2.1.Participants
BLSA participants. BLSA analyses were based on data from 1661 participants (Table 1).
We included visits where participants were cognitively normal or had a clinical diagnosis
of MCI or dementia due to AD. Baseline and last visit were defined for each participant
as the first and last BLSA visit between 1/1992 and 11/2015 where they were aged ≥60
and met the inclusion criteria based on clinical diagnosis and number of available
cognitive scores (see Section 2.2). A total of 7839 visits were selected for analysis. The
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Institutional Review Board of the NIA Intramural Research Program approved the
research protocol for this study, and informed consent was obtained at each visit from all
participants.

WRAP participants. WRAP analyses were based on data from 1542 participants
(Table 1), 72.3% of whom had a family history of AD. We included all visits where
participants were cognitively normal or had a clinical diagnosis of MCI (including an
“early MCI” diagnosis, defined in Section 2.3) or dementia due to AD. Baseline and last
visit were defined for each participant as the first and last WRAP visit up until Wave 5
(inclusive) where they met the inclusion criteria based on clinical diagnosis and number
of available cognitive scores (see Section 2.2). A total of 4467 visits were selected for
analysis. All activities for this study were approved by the Institutional Review Board
and completed in accordance with the Helsinki Declaration.

2.2.Cognitive measures
Eight cognitive measures were selected for our analyses: Trail Making Tests (Trails) A
and B [40] to assess processing speed and executive function, Wechsler Adult
Intelligence Scale (WAIS) digit span forward and backward (revised edition [41] in
BLSA, 3rd edition [42] in WRAP) to assess attention and executive function, California
Verbal Learning Test (CVLT) [43] in BLSA and Rey Auditory Verbal Learning Test
(AVLT) [44] in WRAP measuring immediate recall (sum of total recall across five
learning trials) and 20-minute delayed recall to assess verbal memory, Boston Naming
Test [45] to assess language, and Mini-Mental State Examination (MMSE) [46] to assess
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mental state. Trails A and B were truncated at 300 seconds. All measures were kept in
their original scales. We included visits where at least four of these eight measures were
available. We did not include WAIS digit symbol substitution [41,42] or animal fluency
[47] in our analyses even though they were common to both data sets, since they were
introduced in later stages in BLSA and/or WRAP.

CVLT was added to the BLSA battery in 3/1993 and digit span was added in 1/1992,
while the remainder of the measures were added between 5/1984 and 1/1990. BLSA
participants under age 60 do not receive the Boston naming test as part of their cognitive
battery and did not receive the Trails making test until 2005; therefore, these test scores
were not included. MMSE was added to the WRAP battery in Wave 2, while the
remaining eight measures were available starting with Wave 1 in 2001.

2.3.Clinical Diagnoses
BLSA methods. All BLSA participants are reviewed for cognitive impairment at a
consensus case conference if they have a score ≥4 on the Blessed Information–Memory–
Concentration Test [48], if their Clinical Dementia Rating (CDR) score [49] is ≥0.5 on
the subject or informant report or if they screen abnormal on the Dementia Questionnaire.
Consensus diagnoses are determined by a research team that includes neurologists,
psychiatrists, neuropsychologists, research nurses, and research assistants. Diagnoses of
dementia and AD are based on Diagnostic and Statistical Manual of Mental Disorders 3rd
edition–revised [50] and National Institute of Neurological and Communication
Disorders and Stroke–AD and Related Disorders Association (NINCDS-ADRDA) [51]
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criteria, respectively. Mild cognitive impairment (MCI) is diagnosed based on the
Petersen criteria [52] when cognitive impairment is evident for a single domain or
multiple domains without significant functional loss in activities of daily living. Out of
the eight cognitive measures described in Section 2.2, only Trails A and B, Boston
Naming, and MMSE are used in clinical diagnosis determination.

WRAP methods. WRAP participant visits are reviewed at a consensus case conference if
they meet one or more of the following criteria: 1) cognitive abnormalities relative to
WRAP peers (i.e., at least 1.5 standard deviations below expected relative to robust
internal norms adjusting for age, sex, and literacy-level on the most recent assessment for
factor scores or individual measures of memory, executive function, language, working
memory, or attention [53], [54]; 2) cognitive performance on one or more tests below
values used in other studies as cutpoints for mild cognitive impairment (MCI) diagnoses
(e.g., WMS-R Logical Memory II [55] story A score <9, Alzheimer’s Disease
Neuroimaging Initiative [56]); or 3) an abnormal informant report indicating subjective
cognitive or functional decline. Consensus diagnoses are determined by a research team
that includes physicians, clinical neuropsychologists, and clinical nurse practitioners.
Cognitive statuses include cognitively normal, early MCI, clinical MCI, other cognitive
impairment (e.g., due to other medical conditions), or dementia. The diagnosis of clinical
MCI is based on NIA-AA criteria [57] and includes a) concern regarding change in
cognition, b) impairment in one or more cognitive domains, c) preservation of functional
abilities, and d) does not meet criteria for dementia. The status of early MCI was
developed to identify individuals in the cohort who exhibit lower than expected objective
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performance in one or more cognitive domains (relative to internal robust norms), but
may not yet report subjective cognitive complaints. This experimental construct is
thought to represent a phenotype of early cognitive decline expected to precede a clinical
diagnosis of MCI [54,58]. Dementia diagnosis is based on NINCDS-ADRDA criteria
[51]. Both demented WRAP individuals included in these analyses had dementia due to
AD. The consensus review process was initiated in late 2012. At the time of these
analyses, consensus diagnoses were available for each participant’s last attended study
visit.

2.4.Statistical analyses
2.4.1.Progression score model
We used an improved version [37] of the Progression Score (PS) method [36] to compute
cognitive progression scores (Cog-PS) for individuals in BLSA and WRAP in separate
models using the eight cognitive tests described in Section 2.2 (see Supplementary
Material for details). The Progression Score method is based on a multivariate model that
enables the computation of a score for each visit using a collection of longitudinal
biomarker measures to reflect the state of the visit relative to the rest of the sample. CogPS is an affine transformation of age, and these transformations are allowed to vary
across individuals via subject-specific variables that model inter-subject differences in
rate and baseline levels of progression. The scale of the Cog-PS at the end of the model
fitting procedure is arbitrary (i.e., a Cog-PS of 0 does not convey any meaning on its
own, but compared to a Cog-PS of 1, it indicates better overall performance on the
cognitive measures included in the model). In order to give meaning to the Cog-PS scale,
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we shifted all Cog-PS values such that a Cog-PS of 0 corresponds to the mean value
across cognitively normal individuals, and then scaled all Cog-PS values such that the
standard deviation of Cog-PS among cognitively normal individuals is 1. The Cog-PS
calibration, when combined with the appropriate transformations of the model
parameters, does not affect the likelihood of the model (i.e., the calibrated and
uncalibrated models are identical in terms of their fit to the observed data). This
calibration is intended to make Cog-PS values computed on separate data sets
comparable, with the underlying assumption that cognitively normal groups are
comparable. At the end of model fitting, we obtained Cog-PS for each visit as well as
estimates of cognitive measure trajectories as a function of Cog-PS. The overall
procedure is summarized in Figure S1.

2.4.2.Temporal ordering of cognitive measures
To compare the estimated trajectories for the eight cognitive measures, we linearly scaled
them such that their estimated values at the minimum and maximum Cog-PS observed in
the sample were 0 and 1, respectively. In this standardized space, we refer to a scaled
cognitive value of 0 as “normal” and a scaled cognitive value of 1 as “abnormal”. We
visually evaluated the estimated trajectories to make determinations about temporal
ordering of cognitive changes. To complement this qualitative evaluation, we developed
a procedure that relies on a threshold for each cognitive measure to obtain quantifiable
measures to determine temporal ordering. We transform the midway point of 0.5 in this
standardized space back into the unstandardized scale for each cognitive measure to
obtain a threshold for each cognitive measure. These cognitive measure thresholds are
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not intended for classification of individuals. They rather serve as tools for understanding
the order in which changes begin to appear across cognitive measures. To this end, we
determined the Cog-PS value at which the estimated trajectories surpass the cognitive
measure thresholds. Cognitive measures whose trajectories surpass the threshold at a
lower Cog-PS value are measures that change earlier in the disease process. In order to
provide further evidence for the ordering of cognitive marker changes, we performed 20
bootstrap experiments. The number of bootstrap experiments was limited to 20 due to the
time consuming model fitting procedure. We visualized the resulting trajectories and
compared the Cog-PS values at which measures crossed the threshold across the
bootstrap experiments to quantify the statistical confidence associated with this ordering.

2.4.3.Validation of Cog-PS results
To show evidence for the validity of the individualized Cog-PS, we first investigated
differences in Cog-PS cross-sectionally across diagnosis groups using two-sided
Wilcoxon rank-sum tests. We used the last visit for this analysis since diagnosis was
available only at last visit in WRAP.

To provide further evidence for the temporal ordering of cognitive marker changes, we
used an analysis based on a multi-state Markov model that was independent from the
Cog-PS approach. In this analysis, we used the mean values of the cognitive markers
within the MCI or CI ([M]CI) group at last visit (listed in Table 1) as thresholds for
categorizing each cognitive measure at each visit as being normal or abnormal, with the
exception of MMSE, where we defined abnormality using the conservative threshold
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≤ 25 rather than using the sample mean since there is a strong ceiling effect in our
samples. For Trails A and B, abnormality was defined as being equal to or exceeding the
threshold, and for all other cognitive measures as being equal to or below the threshold.
We considered each pair of cognitive measures, denoted x and y, in separate Markov
models. We categorized each visit into one of the following four states: x and y both
normal (state 1), only x abnormal (state 2A), only y abnormal (state 2B), x and y both
abnormal (state 3). If both x and y were missing, the visit was excluded from analysis. If
only one was available, then the state of the visit was censored accordingly (i.e., if only x
is available and is normal, then the state is either 1 or 2B). We assumed that individuals
need to pass through one of the intermediate states 2A or 2B in order to transition
between states 1 and 3. All other transitions, including backward transitions, were
included in the model, which is summarized in Figure S2. We fitted this multi-state
Markov model using the msm [59] package in R (version 3.2.1) [60]. We are interested in
comparing the transitions out of the first state where both measures are normal. To this
end, we compared the transition rates into States 2A and 2B from State 1.

3.RESULTS
3.1.Temporal ordering of cognitive measures
Estimated cognitive marker trajectories as function of Cog-PS are presented in Figure 1.
While digit span tests have a marked downward slope in the left-hand side of the figure
as a Cog-PS of –2, other cognitive measures do not begin exhibiting marked declines
until later along the Cog-PS scale. CVLT/AVLT measures are next to exhibit declines,
followed by Trails, Boston Naming, and MMSE.
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The standardized cognitive template, obtained by scaling the cognitive measures based on
fitted values corresponding to the minimum and maximum Cog-PS values in the sample,
is presented in Figure 2. The cognitive thresholds obtained by transforming the midway
point along the y-axis back into the unstandardized scale for each cognitive marker are
presented in Table 2, along with the Cog-PS values at which the estimated trajectories
attain these thresholds. In both BLSA and WRAP, digit span forward and backward were
the first measures to attain the cognitive thresholds, followed by CVLT/AVLT immediate
and delayed recall, and finally Trails A and B, Boston naming, and MMSE.

3.2.Validation of Cog-PS results
Cog-PS at last visit was associated with concurrent diagnosis, with cognitively normal
individuals having lower Cog-PS compared to impaired individuals (Figure 3). All
pairwise group comparisons (normal vs. [M]CI, MCI vs. AD, and normal vs. AD) were
significant within each data set (two-sided Wilcoxon rank-sum test, all p<.00002).

Estimated transition rates using the Markov model (Table S2) suggest that cognitive
measures attain the mean level observed in the [M]CI group in the following order in
BLSA: Digit span backward, digit span forward, CVLT immediate, CVLT delayed,
Trails A, Trails B, MMSE, and Boston naming. In WRAP, the ordering is as follows:
digit span forward, digit span backward, AVLT delayed, AVLT immediate, Trails A,
Trails B, and MMSE. Results in WRAP suggest that change in Boston naming occurs
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after digit span backward and before MMSE, but its exact placement among AVLT and
Trails is not clear.

4.DISCUSSION
We applied the progression score model to align individuals in time based on the
similarity of their cognitive marker profiles to learn long-term cognitive trajectories from
shorter-term longitudinal measurements. From this model, we obtained individualized
scores, termed Cog-PS, which we validated by demonstrating their association with
clinical diagnosis. Our analyses were conducted separately on data from two wellcharacterized longitudinal studies of aging, BLSA and WRAP, and revealed similar
results.

Using the estimated trajectories, we showed that digit span tests exhibit their most
extensive dynamic range while individuals are cognitively normal, and that these changes
precede those observed on verbal memory tests, which in turn precede changes on Trails,
Boston naming, and MMSE. The trajectory estimates we obtained using the progression
score model along with their approximate confidence intervals as illustrated in Figure 2
demonstrated this temporal ordering of the cognitive measures. We also used an approach
based on a threshold for each cognitive measure to quantify and complement the findings
of the qualitative assessment.

Our findings about ordering of cognitive changes were validated using a multistate
Markov model. While the Markov model confirmed our finding that digit span measures
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are the first to exhibit changes, followed by changes in CVLT/AVLT, its results
regarding temporal ordering individual cognitive measures were not as consistent
between the two data sets as the Cog-PS model. These discrepancies may be due to the
sensitivity of the Markov model to the cognitive thresholds used to define the states in the
model.

The progression score approach enabled the computation of an individualized indicator of
cognitive performance based on a collection of longitudinal measurements. We
demonstrated that there are statistically significant differences in progression score across
cognitively normal, [M]CI, and AD groups. Since the progression score model is agnostic
to clinical diagnosis, this analysis served as a validation of the computed scores.
However, it should be noted that this is a partial validation since there is a degree of
circularity due to the fact that four out of the eight cognitive measures were used in
diagnosis determination in BLSA, and eight were used in WRAP.

While we used a calibration approach to render the progression scores computed on
BLSA and WRAP comparable, it is important to note that due to differences in the
composition of cognitively normal groups in the two data sets, Cog-PS values do not
convey the same meaning across the studies. Despite this limitation of our methodology,
we found similar temporal cognitive patterns in both studies. Cognitively normal as well
as the [M]CI groups in BLSA had lower cognitive performance on all tests compared to
WRAP. Our scaling procedure for establishing correspondences across cognitive markers
is sensitive to the range of cognitive measurements present in the study. Since this scaling
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procedure is intended to identify normal and abnormal cognitive test values, it is
important that the data set contain measurements spanning the entire normal-to-abnormal
range for each cognitive test. This condition is not fully satisfied in either data set we
considered in this work, particularly in WRAP since WRAP participants are about 18
years younger than BLSA participants on average. Therefore, the scaling procedure may
be less accurate in WRAP than in BLSA, especially for later-changing measures such as
Boston naming and MMSE.

Several previous studies have reported that changes in digit span tests are detectable prior
to a clinical diagnosis of cognitive impairment. For example, a study that evaluated nondemented individuals with subjective memory complaints found that those with normal
digit span scores (as defined using age- and education-adjusted neuropsychological test
scores) at baseline did not exhibit significant declines on verbal memory, visual memory,
or executive function after a mean follow-up of 6.6 years, but had significant declines on
the sum score of digit span forward and backward [61]. On the other hand, age-, sex-, and
education-matched individuals with impaired digit span scores at baseline had significant
declines on tests of verbal learning and animal fluency but not on any other cognitive test.
These findings are in agreement with our estimated ordering of cognitive trajectories on
the path to cognitive impairment, with digit span measures declining first, followed by
measures of verbal memory. Another study that investigated changes in cognition prior to
autopsy in a sample of individuals who remained cognitively normal found that while
longitudinal changes were not significant when assessed separately among individuals
with and without AD neuropathology, longitudinal decline in the attention/working
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memory domain (assessed using digit span forward and backward tests) was greater
among those with neuropathology compared to those without [62]. Other domains,
including episodic memory, language, and executive function, did not show statistically
significant longitudinal differences between the two groups [62].

A limitation of our method is that it does not indicate whether the detected cognitive
changes are due to AD-related mechanisms, and further studies are needed to delineate
normal aging versus disease. Therefore, our results cannot be interpreted as evidence for
using digit span to predict individualized diagnoses. Digit span is not a good predictor of
concurrent diagnosis; using cognitive measure thresholds based on our Cog-PS model to
classify individuals as normal versus [M]CI/AD yields a large number of false positives.
This lack of specificity of digit span for dementia has been documented previously
[63,64]. What our results demonstrate is that changes in digit span are most evident early
on in cognitively normal stages. Detectability of these changes and their associations with
future outcomes at the individual-level, including AD diagnosis in following years or
decades, remain to be fully elucidated; however, prior studies have reported that
sensitivity to change on digit span is small [65]. Another limitation of our method is that
it treats discrete cognitive measures such as digit span as continuous variables, and
therefore may introduce bias into the characterization of their longitudinal trajectories.
Despite these limitations, understanding the association of digit span tests with brain
changes can be informative for designing novel cognitive tests or batteries that are more
sensitive to changes in preclinical AD and that correlate with functional and structural
brain changes over the course of disease.
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Several studies of a small number of healthy individuals found that higher performance
on digit span backward is associated with activation of the right dorsolateral prefrontal
cortex (DLPFC) [66–68], bilateral inferior parietal lobule, anterior cingulate, left DLPFC,
and Broca’s area, with a subset of these regions also implicated in relation to digit span
forward [67,68]. DLPFC is one of the amyloid accumulating regions, and therefore it
may be possible to demonstrate associations between digit span performance and DLPFC
amyloid levels among cognitively normal individuals in studies with large sample sizes.

Analyses conducted in parallel in multiple data sets or in combined samples will
accelerate efforts to further elucidate the relationships among cognitive measures
implicated in preclinical AD. Identifying cognitive measures that are dynamic in
preclinical AD can lead to the development of novel cognitive tests that are finely tuned
to detecting earliest changes. Such measures will facilitate clinical trials aimed at this
early stage by serving as outcome measures that are non-invasive and cheaper to
administer than neuroimaging.
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Table 1. Participants.
Final cognitive status
Age at last visit, mean (SD), y
Range
Male, no. (%)
White, no. (%)
Education, mean (SD), y
Range
Number of visits, mean (SD)
Range
Follow-up duration, mean (SD), y
Range
Trails A at last visit, mean (SD)***
Range
Trails B
Digit span forward
Digit span backward
CVLT/AVLT# immediate recall
CVLT/AVLT delayed recall
Boston naming test
MMSE

Normal
(N=1428)
76.4 (9.0)
60.0–101.0
687 (48%)
1082 (76%)
16.7 (2.7)
8–21
4.5 (3.8)
1–22
7.1 (6.5)
0.0–23.4
38.8 (19.6)
11–300
98.4 (50.2)
26–300
7.7 (2.5)
0–14
6.7 (2.4)
0–14
49.5 (12.4)
0–80
10.2 (3.6)
0–16
53.6 (6.4)
6–60
28.3 (1.8)
13–30

MCI
(N=146)
84.3 (6.4)
68.0–99.3
58 (40%)
128 (88%)
16.2 (2.9)
8–20
5.5 (4.4)
1–23
7.6 (6.2)
0.0–23.0
54.5 (20.8)
21–145
168.6 (70.2)
51–300
7.2 (2.3)
0–13
5.8 (2.1)
0–13
33.1 (9.3)
15–61
5.2 (3.3)
0–13
48.2 (8.0)
18–60
26.4 (2.7)
13–30

BLSA
AD
(N=87)
85.8 (6.7)
66.4–98.6
36 (41%)
76 (87%)
17.2 (2.4)
9–21
6.3 (4.5)
1–22
9.1 (6.5)
0–22.9
87.1 (56.7)
29–300
198.8 (73.9)
78–300
6.2 (2.6)
0–12
4.7 (2.2)
0–11
21.4 (10.6)
0–47
1.7 (2.1)
0–8
42.3 (12.2)
5–58
22.3 (5.9)
0–30

Whole sample
(N=1661)
77.6 (9.2)
60.0–101.0
781 (47%)
1286 (77%)
16.7 (2.7)
8–21
4.7 (3.9)
1–23
7.3 (6.5)
0–23.4
42.3 (25.0)
11–300
106.2 (57.8)
26–300
7.6 (2.5)
0–14
6.5 (2.4)
0–14
46.8 (14.1)
0–80
9.5 (4.1)
0–16
52.6 (7.4)
5–60
27.8 (2.6)
0–30

Normal
(N=689)
61.2 (6.7)
42–76
209 (30%)
654 (95%)
16.3 (2.8)
12–29
3.4 (0.8)
1–5
7.6 (2.2)
0–13
25.3 (8.0)
11–85
59.7 (20.7)
24–169
10.7 (2.2)
5–16
7.4 (2.2)
2–14
52.7 (7.5)
34–72
11.0 (2.6)
1–15
57.8 (2.5)
36–60
29.4 (0.9)
24–30

WRAP
CI*
(N=147)
63.2 (6.8)
44–76
63 (43%)
136 (92%)
16.1 (3.2)
10–26
3.4 (0.7)
1–5
7.9 (2.2)
0–12
31.4 (10.1)
13–63
84.4 (35.6)
29–300
9.9 (2.3)
5–16
6.3 (2.3)
2–13
41.5 (8.1)
21–62
7.5 (3.1)
0–15
56.6 (4.0)
40–60
29.0 (1.3)
24–30

Whole sample
(N=1542**)
59.9 (7.3)
38–78
454 (30%)
1374 (89%)
16.1 (2.9)
9–29
2.9 (1.2)
1–5
6.2 (3.5)
0–13
27.2 (9.6)
9–110
67.3 (32.5)
24–300
10.4 (2.2)
4–16
7.1 (2.2)
2–14
50.2 (8.8)
21–72
10.3 (3.1)
0–15
56.9 (3.8)
30–60
29.3 (1.0)
23–30

* Cognitively impaired (CI) group in WRAP includes both clinical MCI (N=19) as well as individuals who were determined to have early MCI based on internal norms for
cognitive measures (N=128).
** Not all WRAP participants had consensus diagnosis data. Two participants were diagnosed with dementia due to Alzheimer’s disease at last visit.
*** All cognitive measure statistics are computed using available values at last visit and reported as mean (SD); Range.
# Verbal memory is measured using CVLT in BLSA and AVLT in WRAP.
BLSA = Baltimore Longitudinal Study of Aging; WRAP = Wisconsin Registry for Alzheimer’s Prevention; CI = Cognitive impairment; MCI = Mild cognitive impairment; AD =
Alzheimer’s disease; SD = standard deviation; CVLT = California verbal learning test; AVLT = Auditory verbal learning test; MMSE = Mini mental state exam
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Figure 1a.
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Figure 1b.

Figure 1. Cognitive measure trajectories in (a) BLSA and (b) WRAP. Gray, blue, and red dots indicate cognitively normal, MCI or CI
([M]CI), and AD visits, respectively. Visits where consensus diagnoses are not available are indicated as unfilled circles.
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Figure 2. Scaled cognitive trajectories obtained using (a) BLSA and (b) WRAP data.
Dotted line in the top panel corresponds to the midway point between Normal and
Abnormal. Line segments in the bottom panel indicate the range of the Cog-PS values
that attain the midway point (i.e., cognitive threshold) across 20 bootstrap experiments.

Table 2. Cognitive measure thresholds computed on the whole sample. Minimum and
maximum values obtained across 20 bootstraps are indicated in parentheses.
BLSA
Cognitive
measure
Trails A
Trails B
Digit span
forward
Digit span
backward
CVLT/AVLT
immediate
CVLT/AVLT
delayed
Boston
naming
MMSE

Threshold
49.5
(46.5–300.0)
127.3
(108.7–300.0)
9.5
(9.47–14.0)
8.4
(8.4–14.0)
50.6
(46.5–50.6)
10.3
(10.3–11.3)
42.0
(41.8–51.6)
25.6
(13.7–25.6)

Cog-PS at
threshold
1.26
(0.90–3.07)
0.98
(0.69–1.05)
-1.38
(-2.54– -1.38)
-1.26
(-2.53– -1.26)
0.04
(-0.16–0.16)
0.13
(-0.25–0.13)
2.01
(0.42–2.01)
2.32
(2.32–3.05)

WRAP
Cog-PS at
Threshold
threshold
34.3
2.10
(29.9–43.0)
(1.03–2.48)
107.3
2.32
(93.6–167.3)
(2.03–2.59)
11.4
-0.95
(11.2–11.5)
(-0.95– -0.46)
8.6
-1.17
(8.4–9.0)
(-1.21– -0.91)
49.5
0.38
(48.1–50.2)
(0.30–0.65)
10.0
0.40
(9.7–10.3)
(0.28–0.67)
51.8
2.39
(32.0–54.2)
(1.86–2.76)
28.8
1.73
(28.0–29.2)
(0.89–2.45)
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Figure 3. Box plot of Cog-PS by clinical diagnosis at last visit in BLSA (left) and WRAP
(right). Central mark is the median, edges of the box correspond to the interquartile
range, and whiskers extend to the range of non-outlier Cog-PS values. Outliers are
plotted individually. All pairwise group comparisons were significant within each data set
(two-sided Wilcoxon rank-sum test, p < 0.00002).
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SUPPLEMENTARY MATERIAL
Progression Score Model
For clarity, vector-valued variables are in bold and matrices are capitalized. The
affine transformation between the age !"# of subject $ at visit % and the Cog-PS &"# is
given by
&"# = (" !"# + *" ,
where (" and *" are the subject-specific variables assumed to be independent and
identically distributed across subjects with a bivariate normal distribution ,(., /). ("
and *" model the rate of change and baseline level of Cog-PS, respectively.
The trajectory of cognitive measure 1 is assumed to be a sigmoid in Cog-PS, and
is given by
23 &; 53 =

1+

63
9:
8 ; (<9=; )

+ >3 ,

where 53 = (63 , ?3 , @3 , >3 ) are trajectory parameters to be estimated. >3 and 63 + >3
correspond to the minimum and maximum values of the sigmoid, respectively. @3 is the
inflection point (the Cog-PS value at which the second derivative is zero) and 63 ?3 4 is
the slope at the inflection point.
The observed cognitive measures B"#3 stacked into the vector C"# are assumed to
have additive normally distributed noise, and are described by
C"# = D &; 5 + E"# ,
where D is the vector obtained by stacking 23 , and E"# is noise, assumed to be
independent and identically distributed with a multivariate normal distribution ,(F, G). G
is an unstructured covariance matrix that represents the variance of noise for each
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cognitive measure as well as the correlations among them, and is estimated during the
model fitting procedure.
Model fitting is performed using a Monte Carlo expectation-maximization
(MC-EM) algorithm. The subject-specific variables and missing cognitive measures
constitute the hidden variables in this framework. Model parameters include 5, ., /, and
G. The EM approach is an iterative procedure where the most likely values of the hidden
variables are computed given the data and current parameter estimates, and then the
model parameters are estimated using these most likely values for the hidden variables.
Since the integral in the E-step for our model does not have an analytical form, we
approximate it using Monte Carlo samples.
After model fitting, we compute the cross-sectional mean and variance of the
Cog-PS among cognitively normal individuals:
H=

1
ΩJKLMNO

Z[ =

&"#P ,
"∈RSTUVWX

1
ΩJKLMNO

(&"#P − H)[
"∈RSTUVWX

where %] is the visit index at which the mean and variance are computed and ΩJKLMNO is
the set of individuals who are cognitively normal at visit %] . For BLSA, %] corresponds to
the baseline visit, and for WRAP to the last visit (since diagnosis information is available
∗
only at last visit). We calibrate the Cog-PS scale as &"#
=

<_` 9a
b

, which corresponds to the

following changes in the subject-specific variables:
("
1
("∗
.
∗ =
*
*"
Z " −H
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This calibration is accompanied by the following standardization of the model
parameters:
?3∗ = Z?3 ,
@3∗ =
.∗ =

@3 − H
,
Z

1
0
.−
,
H
Z

/∗ =

1
/.
Z[

Let the minimum and maximum progression scores observed in the data set after
model fitting be &MeJ and &MNf . We scale the trajectory of each marker so that fitted
values at these values correspond across markers. Scaled values are given by
(ghNOij)

23

&; 53 =

23 &; 53 − 23 &MeJ ; 53
.
23 &MNf ; 53 − 23 &MeJ ; 53
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Figure S1. Diagram illustrating progression score (PS) model fitting, PS calibration, and
cognitive measurement scaling to obtain standardized space of cognitive markers. Lower
values for the illustrated cognitive markers indicate lower cognitive performance. PS
values are calibrated such that lower progression scores indicate better overall cognitive
performance.
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Multi-state Markov model

Figure S2. Multi-state Markov model. Each node corresponds to one of the four states in
the model. x and y correspond to cognitive measures. Normal and abnormal
categorization of the cognitive measures are based on thresholding at the mean value
within the [M]CI group at last visit.

We present detailed results comparing digit span forward and CVLT delayed recall tests
in BLSA. Table S1 presents the counts of consecutive states in the BLSA, and Figure S3
displays the estimated transition rates. Since we did not characterize transition rates by
age, our results represent the transition rates for an individual at the sample mean age.

Table S1. Summary of the BLSA data as a frequency table of pairs of consecutive states
for x=Digit span forward and y=CVLT delayed recall.
From \ To
State 1
State 2A
State 2B
State 3
State 1
2056
593
81
41
State 2A
524
1204
27
99
State 2B
56
16
89
27
State 3
24
48
35
135
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Figure S3. Multi-state Markov model for x=Digit span forward and y=CVLT delayed
recall. Transition rates per 100 person-years, estimated using BLSA data, are shown next
to the arrows. 95% confidence intervals for the transition rates are in parentheses.

Assuming an initial cohort consisting of 100 individuals in State 1 at baseline, the model
estimates that approximately 53 of them would be in State 1, 37 in State 2A, 4 in State
2B, and 6 in State 3 after a follow-up of 7.3 years (the mean follow-up duration in the
BLSA).

Transition rates out of state 1 are shown in Table S2 for all Markov models fitted using
each pair (x,y) of cognitive tests.
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Cognitive measure pair (x,y)
x
y
Trails A
Trails B

BLSA
WRAP
State 1 à 2A
State 1 à 2B
State 1 à 2A
State 1 à 2B
4.20
3.28
6.79
2.88
(3.57–4.95)
(2.70–3.98)
(5.77–8.00)
(2.22–3.75)
Digit span
4.62
18.89
6.65
7.23
forward
(3.74–5.72)
(17.31–20.62)
(5.54–7.98)
(6.23–8.40)
Digit span
4.33
11.21
6.11
11.47
backward
(3.63–5.16)
(10.10–12.43)
(4.95–7.54)
(9.94–13.24)
CVLT/AVLT
4.38
4.10
6.75
2.78
immediate
(3.76–5.10)
(3.50–4.80)
(5.75–7.92)
(2.23–3.48)
CVLT/AVLT
4.25
3.74
7.04
3.39
delayed
(3.66–4.93)
(3.20–4.38)
(5.99–8.26)
(2.79–4.13)
Boston naming
4.82
2.46
7.19
4.16
(4.15–5.60)
(2.08–2.91)
(6.07–8.50)
(3.49–4.96)
MMSE
4.95
2.70
7.40
0.42
(4.32–5.67)
(2.19–3.32)
(6.46–8.48)
(0.15–1.18)
Trails B
Digit span
2.94
19.21
3.18
7.19
forward
(2.21–3.91)
(17.63–20.93)
(2.48–4.07)
(6.27–8.24)
Digit span
3.00
10.89
3.52
11.81
backward
(2.41–3.73)
(9.83–12.07)
(2.65–4.68)
(10.39–13.43)
CVLT/AVLT
4.04
3.72
3.17
3.12
immediate
(3.41–4.78)
(3.15–4.39)
(2.58–3.89)
(2.59–3.76)
CVLT/AVLT
3.99
3.24
3.63
3.40
delayed
(3.37–4.73)
(2.74–3.84)
(2.99–4.41)
(2.83–4.08)
Boston naming
4.17
2.30
4.32
3.60
(3.54–4.91)
(1.94–2.74)
(3.51–5.31)
(3.00–4.32)
MMSE
4.08
2.28
4.48
0.2
(3.49–4.76)
(1.84–2.83)
(3.83–5.24)
(0.06–0.75)
Digit span
Digit span
16.98
8.10
4.79
9.52
forward
backward
(15.30–18.83)
(6.67–9.83)
(3.81–6.02)
(8.05–11.26)
CVLT/AVLT
18.77
3.43
7.08
3.31
immediate
(17.21–20.47)
(2.68–4.41)
(6.18–8.11)
(2.67–4.11)
CVLT/AVLT
19.21
3.42
7.16
3.68
delayed
(17.63–20.93)
(2.71–4.31)
(6.21–8.25)
(3.02–4.49)
Boston naming
18.64
2.06
7.31
3.64
(17.07–20.36)
(1.60–2.67)
(6.32–8.46)
(2.94–4.50)
MMSE
19.13
2.81
7.72
0.45
(17.58–20.81)
(1.93–4.11)
(6.83–8.73)
(0.12–1.74)
Digit span
CVLT/AVLT
11.55
3.86
11.21
3.14
backward
immediate
(10.43–12.78)
(3.14–4.75)
(9.82–12.79)
(2.42–4.06)
CVLT/AVLT
11.75
3.48
11.04
3.62
delayed
(10.62–13.01)
(2.86–4.23)
(9.66–12.62)
(2.88–4.54)
Boston naming
11.53
2.12
11.48
3.40
(10.39–12.80)
(1.72–2.61)
( 9.99–13.19)
(2.68–4.30)
MMSE
11.82
3.52
12.06
0.48
(10.70–13.06)
(2.66–4.65)
(10.73–13.57)
(0.17–1.33)
CVLT/AVLT
CVLT/AVLT
3.35
2.78
2.82
2.90
immediate
delayed
(2.58–4.37)
(2.17–3.57)
(2.16–3.69)
(2.29–3.67)
Boston naming
3.58
2.14
3.17
3.81
(3.07–4.19)
(1.79–2.55)
(2.59–3.87)
(3.21–4.52)
MMSE
4.38
3.13
3.72
0.07
(3.75–5.12)
(2.54–3.86)
(3.19–4.33)
(0.01–0.56)
CVLT/AVLT
Boston naming
3.77
2.12
3.40
3.85
delayed
(3.24–4.38)
(1.78–2.53)
(2.80–4.13)
(3.24–4.59)
MMSE
3.87
2.92
4.06
0.16
(3.31–4.52)
(2.35–3.63)
(3.50–4.71)
(0.04–0.71)
Boston naming
MMSE
2.44
2.92
4.43
0.41
(2.07–2.86)
(2.36–3.60)
(3.82–5.14)
(0.15–1.12)
Table S2. State transition rates per 100 person-years. 95% confidence intervals are in parentheses. The higher
transition rate is in bold whenever it is statistically different from the lower rate based on 95% CIs. If the State 1 à 2A
transition rate is higher, the measure listed under column x becomes abnormal before y. If the State 1 à 2B transition
rate is higher, the measure listed under column y becomes abnormal before x.
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